Top

Published in:

Open Access 01-12-2020 | SARS-CoV-2 | Editorial

Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?

Authors: Carlo Torti, Maria Mazzitelli, Enrico Maria Trecarichi, Owachi Darius

Published in: BMC Infectious Diseases | Issue 1/2020

Abstract

The SARS-CoV-2, which emerged from East Asia in December 2019, has rapidly evolved into a global pandemic infecting close to 7 million people. The current uncertainties regarding its impact on Africa calls for critical monitoring of the evolution of the pandemic and correlation of factors that influence the burden of the disease. We herein discuss possible implications of SARS-CoV-2 on the African continent.

Petersen E, Petrosillo N, Koopmans M, Beeching N, Di Caro A, Gkrania-Klotsas E, et al. Emerging infections—an increasingly important topic: review by the emerging infections task force. Clin Microbiol Infect. 2018;24:369–75.CrossRef

Candido DDS, Watts A, Abade L, Kraemer MUG, Pybus OG, Croda J, et al. Routes for COVID-19 importation in Brazil. J Travel Med. 2020;27:taaa042.CrossRef

Zhang XA, Fan H, Qi RZ, Zheng W, Zheng K, Gong JH, et al. Importing coronavirus disease 2019 (COVID-19) into China after international air travel. Travel Med Infect Dis. 2020;101620.

Haider N, Yavlinsky A, Simons D, Osman AY, Ntoumi F, Zumla A, et al. Passengers’ destinations from China: low risk of novel coronavirus (2019-nCoV) transmission into Africa and South America. Epidemiol Infect. 2020;148:e41.CrossRef

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.CrossRef

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–9.CrossRef

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-NCOV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382:970–1.CrossRef

Stadnytskyi V, Bax CE, Bax A, Anfinrud P. The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. Proc Natl Acad Sci. 2020;117:11875–7.CrossRef

Somsen GA, van Rijn C, Kooij S, Bem RA, Bonn D. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Lancet Respir Med. 2020;S2213–2600(20):30245–9.

10.

Prather KA, Wang CC, Schooley RT. Reducing transmission of SARS-CoV-2. Science. 2020:eabc6197. https://doi.org/10.1126/science.abc6197.

11.

Clifford SJ, Klepac P, Van Zandvoort K, Quilty BJ, Eggo RM, Flasche S. Interventions targeting air travellers early in the pandemic may delay local outbreaks of SARS-CoV-2. medRxiv. 2020. doi.org/https://doi.org/10.1101/2020.02.12.20022426.

12.

Bwire GM, Paulo LS. Coronavirus disease-2019: is fever an adequate screening for the returning travellers? Trop Med Health. 2020;48:14.CrossRef

13.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.CrossRef

14.

PAHO. WHO Characterizes COVID-19 as A Pandemic. World Health Organization. 2020. https://www.paho.org/en/news/11-3-2020-who-characterizes-covid-19-pandemic. Accessed 9 June 2020.

15.

WHO. Coronavirus disease (COVID-19) pandemic. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (accessed May 21 2020).

16.

WHO. COVID-19 situation report 29. Coronavirus Dis 2019. 2020 (accessed June 9 2020).

17.

Kapata N, Ihekweazu C, Ntoumi F, Raji T, Chanda-Kapata P, Mwaba P, et al. Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future. Int J Infect Dis. 2020;93:233–6.CrossRef

18.

WHO. Laboratory testing strategy recommendations for COVID-19: interim guidance. 2020 (accessed June 9 2020).

19.

COVID-19 IPMU. No Title. 2020. https://covid19.gou.go.ug. (accessed May 21 2020).

20.

Senegal’s $1 COVID-19 test kit and the race for a vaccine. 2020. https://www.aljazeera.com/programmes/countingthecost/2020/04/senegal-1-covid-19-test-kit-race-vaccine-200425131112353.html. (accessed May 21 2020).

21.

Kavanagh MM, Erondu NA, Tomori O, Dazau VJ, Okiro EA, Maleche A, et al. Access to lifesaving medical resources for african countries: COVID-19 testing and response, ethics, and politics. Lancet. 2020;395:1735–8.CrossRef

22.

Morawska L, Cao J. Airborne transmission of SARS-CoV-2: the world should face reality. Environ Inter. 2020;139:105730.CrossRef

23.

Armah FA, Ekumah B, Yawson DO, Odoi JO, Afitiri AR, Nyieku FE. Access to improved water and sanitation in sub-Saharan Africa in a quarter-century. Heliyon. 2018;4:e00931.CrossRef

24.

Heller L, Mota CR, Greco DB. COVID-19 faecal-oral transmission: are we asking the right questions? Sci Total Environ. 2020;729:138919.CrossRef

25.

Racelma K. Towards African cities without slums. 2020. https://www.un.org/africarenewal/magazine/april-2012/towards-african-cities-without-slums. (accessed May 21 2020).

26.

Corburn J, Vlahov D, Mberu B, Riley L, Caiaffa WT, Rashid SF, et al. Slum health: arresting COVID-19 and improving well-being in urban informal settlements. J Urban Heal. 2020:1–10.

27.

WHO. Shortage of personal protective equipment endangering health workers worldwide. 2020. https://www.who.int/news-room/detail/03-03-2020-shortage-of-personal-protective-equipment-endangering-health-workers-worldwide. (accessed May 21 2020).

28.

Omoleke SA, Mohammed I, Saidu Y. Ebola viral disease in West Africa: a threat to global health, economy and political stability. J Public Health Afr. 2016;7:534.PubMedPubMedCentral

29.

Ministry of Health of Kenya. Coronavirus - Kenya: Mass Production of Personal Protective Equipment (PPE). 2020. https://www.africa-newsroom.com/press/coronavirus-kenya-mass-production-of-personal-protective-equipment-ppe. (accessed May 21 2020).

30.

UNAIDS. Uniting behind a people’s vaccine against COVID-19. 2020. https://www.unaids.org/en/resources/presscentre/featurestories/2020/may/20200514_covid19-vaccine-open-letter. (accessed May 21 2020).

31.

Kamadjeu R. The future of routine immunization in Africa. Pan Afr Med J. 2017;27(Suppl 3):1.PubMedPubMedCentral

32.

Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS. 2011;25:367–77.CrossRef

33.

Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.

34.

Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384.CrossRef

35.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020. doi.org/https://doi.org/10.1101/2020.04.10.20060558.

36.

Mehra MR, Desai SS, Ruschitzka F, Patel AN, et al. Lancet. 2020;S0140–6736(20):31180–6.

37.

Boulware D, Pullen M, Bangdiwala A, Pastick K, Logfren S, Okafor E, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2016638.

38.

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2007764.

39.

Gilead. Remdesivir Clinical Trials. 2020. https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials. (accessed Jun 7 2020).

40.

Sayad B, Sobhani M, Khodarahmi R. Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial? Arch Med Res. 2020;S0188–4409(20):30551–8.

41.

Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313.CrossRef

42.

Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020. doi.org/https://doi.org/10.1101/2020.03.30.20048058.

43.

Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020. https://doi.org/10.1002/jmv.25897.

44.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single-centre experience. J Med Virol. 2020. https://doi.org/10.1002/jmv.25801.

45.

Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, et al. Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. J Med Virol. 2020. https://doi.org/10.1002/jmv.26016.

46.

Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ. 1985;63:965–81.PubMedPubMedCentral

47.

Diop EHA, Queiroz EF, Kicka S, Rudaz S, Diop T, Soldati T, et al. Survey on medicinal plants traditionally used in Senegal for the treatment of tuberculosis (TB) and assessment of their antimycobacterial activity. J Ethnopharmacol. 2018;216:71–8.CrossRef

48.

Tugume P, Nyakoojo C. Ethno-pharmacological survey of herbal remedies used in the treatment of paediatric diseases in Buhunga parish, Rukungiri District, Uganda. BMC Complement Altern Med. 2019;19:353.CrossRef

49.

Njoroge GN, Bussmann RW. Traditional management of ear, nose and throat (ENT) diseases in Central Kenya. J Ethnobiol Ethnomed. 2006;2:54.CrossRef

50.

Tih Felix RS. Madagascar’s president endorses herbal drink to combat COVID-19. 2020. https://www.aa.com.tr/en/africa/madagascars-president-endorses-herbal-drink-to-combat-covid-19/1822383. (accessed May 21 2020).

51.

Worldometers African Populations. No Title. 2020. https://www.worldometers.info/world-population/africa-population/ (accessed May 21 2020).

52.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.

53.

Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv. 2020. doi: doi.org/https://doi.org/10.1101/2020.01.26.919985.

54.

Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery. 2020;6:11.CrossRef

55.

WHO Regional Office for Africa. No Title. Strategic plan to reduce malnutrition in Africa adopted by WHO Member States. 2020. https://www.afro.who.int/news/strategic-plan-reduce-malnutrition-africa-adopted-who-member-states. (accessed May 21 2020).

56.

WHO Regional Office for Africa. No Title. 2020. https://www.afro.who.int/health-topics/tuberculosis-tb. (accessed May 21 2020).

57.

UNAIDS-Fact sheet. No Title. 2020. https://www.who.int/hiv/mediacentre/200605-FS_SubSaharanAfrica_en.pdf. (accessed May 21 2020).

58.

Murthy S, Leligdowicz A, Adhikari NKJ. Intensive care unit capacity in low-income countries: a systematic review. PLoS One. 2015;10:e0116949.CrossRef

59.

Atumanya P, Sendagire C, Wabule A, Mukisa J, Ssemogerere L, Kwizera A, et al. Assessment of the current capacity of intensive care units in Uganda; a descriptive study. J Crit Care. 2020;55:95–9.CrossRef

60.

Africa WRO for. No Title. New WHO estimates: Up to 190 000 people could die of COVID-19 in Africa if not controlled. 2020. https://www.afro.who.int/news/new-who-estimates-190-000-people-could-die-covid-19-africa-if-not-controlled. (accessed May 21 2020).

61.

Rampa F. ecdpm Making policies work. Breiefing note No. 117. One Health and COVID-19: global leadership, territorial investment and food systems. https://ecdpm.org/wp-content/uploads/One-Health-COVID-19-Global-leadership-territorial-investment-food-systems-briefing-note-117-ECDPM.pdf. Accessed 9 June 2020.

Title: Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?
Authors: Carlo Torti
Maria Mazzitelli
Enrico Maria Trecarichi
Owachi Darius
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: SARS-CoV-2
COVID-19
Coronavirus
Published in: BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-020-05147-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Disseminated Bacillus Calmette–Guérin (BCG) infection and acute exacerbation of interstitial pneumonitis: an autopsy case report and literature review

Trends in microbial profile of burn patients following an event of dust explosion at a tertiary medical center

Bacterial otitis media in sub-Saharan Africa: a systematic review and meta-analysis

Characteristics of tuberculosis patients in the integrated tuberculosis control model in Chongqing, China: a retrospective study

Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis

Revealing two dynamic dengue epidemic clusters in Thailand

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage